Ultrasound
Cardio-oncology
Managing cardiotoxicity risks at every step
Because cancer patients have on average a 2-6 times higher cardiovascular disease mortality risk than the general population1, prompt, reliable identification of at-risk patients is crucial. And once treatment is underway, close monitoring could help cardiologists detect potential biomarkers that may indicate the early stages of cardiac toxicity. The European Society of Cardiology (ESC) Guidelines for Cardio-oncology2 reflect the priorities for the prevention and monitoring of cardiotoxicity risks.
Solutions in line with ESC Guidelines on cardio-oncology
We are ready to support you and your patients every step of the way along their cancer treatment journey. Our AI-based ultrasound solutions support a comprehensive baseline assessment and reduce variability between users. Powerful workflow solutions provide multidisciplinary cardio-oncology teams with a patient-centric overview.
Assess and manage cardiotoxicity with confidence
- Access patient data, including ECG, blood pressure, biomarker data and high-quality images, in a longitudinal patient-centric view.
- Define robust baseline risk predictors for cardiotoxicity by performing risk stratification assessments using a highly standardized, easy-to-follow approach.
- Capture superb images and robust quantification for accurate and consistent measurements that inform and guide the patient journey.
- In less than three minutes, gather the necessary data to inform stratification and treatment frequency decisions.3
Advanced tools provide insights
- AutoStrain provides automated, robust and reproducible global longitudinal (GLS) strain measurement with a single button push.
- Dynamic HeartModel* measures 3D ejection fraction (3DEF) in seconds as part of a routine workflow, harnessing AI for enhanced cardiac function assessments.
- iRotate keeps the transducer in a fixed position, facilitating reproducible images and helping bridge the gap between 2D and 3D thinking.
1/3
Enabling technologies
Give patients access to your team’s full expertise, regardless of location. Learn more.
Footnotes
- Cancer patients are at higher risk of dying from heart disease and stroke www.escardio.org/The-ESC/Press-Office/Press-releases/Cancer-patients-are-at-higher-risk-of-dying-from-heart-disease-and-stroke
- Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., De Azambuja, E., De Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244.
- López-Fernández, T.MD Cardiac Imaging Laboratory, Cardio-oncology unit, Hospital La Paz Institute for Health Research, Madrid, Spain, “Using advanced ultrasound tools to assess CTRCD (cancer therapy-related cardiac dysfunction), 2020.
Disclaimer
*HeartModel, previously sold under the name HeartModel A.I., is an advanced automation solution, not currently certified as artificial intelligence.
**Copyright Myocardial Solutions, Inc. 2021. All rights reserved.
***Philips Cardiovascular Workspace is the commercial name of the medical device Philips IntelliSpace Cardiovascular.